Fate Therapeutics Inc (NASDAQ:FATE) – Research analysts at Wedbush issued their FY2022 earnings estimates for Fate Therapeutics in a note issued to investors on Thursday. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will post earnings of $0.90 per share for the year. Wedbush has a “Outperform” rating and a $7.00 price objective on the stock.
Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics had a negative return on equity of 84.90% and a negative net margin of 1,041.33%. The firm’s revenue was up .0% on a year-over-year basis.
Shares of Fate Therapeutics (NASDAQ:FATE) traded up $0.19 during trading hours on Monday, hitting $7.37. 413,600 shares of the stock were exchanged, compared to its average volume of 525,577. The company has a market cap of $414.48, a price-to-earnings ratio of -7.76 and a beta of 1.52. Fate Therapeutics has a 1 year low of $2.52 and a 1 year high of $7.40. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32.
Several institutional investors have recently made changes to their positions in the company. 683 Capital Management LLC boosted its stake in shares of Fate Therapeutics by 15.4% in the 3rd quarter. 683 Capital Management LLC now owns 678,800 shares of the biopharmaceutical company’s stock valued at $2,688,000 after purchasing an additional 90,563 shares in the last quarter. Neuberger Berman Group LLC boosted its stake in shares of Fate Therapeutics by 167.6% in the 3rd quarter. Neuberger Berman Group LLC now owns 133,000 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 83,300 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Fate Therapeutics in the 3rd quarter valued at $234,000. Hochman Cole Investment Advisors Inc. purchased a new stake in shares of Fate Therapeutics in the 3rd quarter valued at $158,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Fate Therapeutics in the 3rd quarter valued at $367,000. 49.86% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Equities Analysts Offer Predictions for Fate Therapeutics Inc’s FY2022 Earnings (FATE)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/22/equities-analysts-offer-predictions-for-fate-therapeutics-incs-fy2022-earnings-fate.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.